Immunic Inc (IMUX NASDAQ) stock market data APIs
$0.684
0.04(5.8%)
as of July 1, 2025
Try our APIs with
free plan!
Immunic Inc Financial Data Overview
Price chart is built with
Anychart
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Prev. Close
0.684
Open
0.7198
High
0.746
Low
0.684
52 wk Range
0.561-2.11
Market Cap
66 833 K
Shares Outstanding
95 818 K
EPS
-0.25
Beta
1.486
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunic Inc data using free add-ons & libraries
Get Immunic Inc Fundamental Data
Immunic Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -100 845 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-11
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunic Inc News
New
Immunic reports low disability worsening rates in MS drug trial
NEW YORK - Immunic, Inc. (NASDAQ:IMUX) announced Tuesday that 92.3% of patients treated with its experimental multiple sclerosis drug vidofludimus calcium remained free of 12-week confirmed disability...
Insider Purchase: CEO and Director of $IMUX Buys 15,000 Shares
Daniel Vitt, the CEO and Director of $IMUX, bought 15,000 shares of the company on 06-04-2025 for an estimated $11,550. This trade was reported by Quiver Quantitative using data from a recent SEC fili...
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis – – P...
Immunic to Participate in Investor and Scientific Conferences in August
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
